Suzhou Sciscape Biomedicine Science & Technology Co. Ltd.

Institute of Radiation Medicine, Academy of Military Medical Sciences, People's Liberation Army of China

Pinghu Sciscape Bio-Pharmaceutical Technology Co., Ltd.

Beijing Bailening Biotechnology Co., Ltd.

Suzhou Sciscape Bio-Pharmaceutical Technology Co. Ltd.

Beijing Threeman Medicine Science and Technology Limited Company

Chenggang Zhang

Zhihui Li

Yan Gao

Yang Xu

Yanchun Zhang

Junhuai Li

Yonghong Wu

Weiguang Li

Yu Li

Tingfang Chen

Lihong Wang

Aijia Shang

A multi-functional composition is disclosed as well as the preparation method and applications thereof. The composition contains a marine algae-derived material and an enzyme inhibitor. The marine algae-derived material is one from the group consisting of natural algal saccharide, alginic acid and alginate or is a mixture of several of them. The enzyme inhibitor is an inhibitor to the enzyme decomposing the material derived from marine algae.

Multi-functional composition and preparation method and application thereof

The application ofderivative CZLC31 fromin preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.

[object Object]

The application of flagellin derivative CZLC31 fromin preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.

Growing community of inventors

Beijing, China

Chenggang Zhang